Adam O’Dell is the chief investment strategist at Money & Markets and the founder of Green Zone Fortunes, the service behind the “Imperium” pitch currently making the rounds. If you have watched that presentation, or caught one of its earlier runs, you know the voice: a numbers-first analyst arguing that a specific technology is crossing from interesting to inevitable, and that the stocks tied to it are about to reprice. This piece is about the analyst himself, where he came from, what he has gotten right, and how the Imperium thesis fits into a career built on systematic, data-driven stock ratings.

Who Is Adam O’Dell?

O’Dell’s public identity is built on a single, checkable claim: he scores stocks. His signature tool, the Green Zone Power Ratings system, rates thousands of equities and sorts them into a green zone of buys and a red zone of sells using momentum, value, and volatility inputs. That is a real, consistent framework, and it gives his recommendations a discipline that a lot of newsletter pitches do not have. He runs three services under the Money & Markets umbrella: Green Zone Fortunes, his flagship, plus Cycle 9 Alert and 10X Profits.

The man behind the model comes from a background in financial research and data rather than pure storytelling, and it shows. His presentations lean on charts, catalysts, and timing windows more than on personalities. For a reader trying to decide whether to trust a pitch, that is a meaningful difference from the typical teaser.

The Palantir Call and the Green Zone Method

The strongest entry on O’Dell’s recent resume is well documented. He began teasing Palantir in the spring of 2024, when the stock was still trading in the $20s, and it went on to be the best-performing stock in the S&P 500 for 2024. That is a dated, verifiable win on a large, liquid company, and the Imperium presentation leans on it correctly as evidence that he can spot a “zero to one” business before the crowd does.

The method behind the call matters as much as the call itself. O’Dell is a quant at heart. He treats a stock rating the way an engineer treats a signal: gather the inputs, run the screen, and let the score do the talking. When he points to Palantir as a career-defining call, the claim sits on top of a system, not on a hunch. That is the reason his pitches deserve a serious read even when the headline numbers in them are enormous.

The Imperium Thesis

The current pitch, “Imperium: The No. 1 Investment for 2027,” is O’Dell’s spin on synthetic biology, and he builds it around a memorable line: “Once you can read, design, and write the code of living things, every industry that sells an animal, a plant, a fiber, or a molecule is suddenly just a software problem.”

From there he maps a familiar three-layer stack onto three companies. Twist Bioscience is the silicon layer, the “Intel” of the DNA revolution. Ginkgo Bioworks is the software layer, the “Microsoft.” Absci is the apps layer, with a baldness drug called ABS-201 as the flagship application. The framing borrows directly from the personal-computer era, and it is a clean way to make an unfamiliar field feel legible to a general investor.

O’Dell also brings the scale numbers, citing McKinsey’s estimate that the technology could “disrupt 60% of the physical inputs in the global economy” across industries worth roughly $65 trillion. Those are the kind of figures that make a pitch feel urgent, and they deserve the same scrutiny we gave his earlier data-center electrical pitch in our Tech-Opoly teardown.

The Track Record, Honestly

The honest version of O’Dell’s Imperium history is more mixed than the Palantir line suggests. He first teased Twist Bioscience as his Imperium play in February 2021, when the stock was in the $120s, and kept promoting it through the brutal biotech drawdown of 2022 and 2023. In the spring of 2024 he swapped Twist out for Pacific Biosciences, a call that never worked out, and he has now returned to Twist for the 2027 edition.

None of that makes him wrong this time, and it does not take away from a genuinely impressive Palantir call. What it means is that Imperium is a recurring, refreshable theme rather than a one-time revelation, and the specific names under it have changed over the years. For a reader, that is useful context: judge the analyst on the consistency of his method, not on the assumption that every pick lands. We covered the third pick in the stack, Absci, in our Absci AI drug discovery teardown.

What to Weigh Before Subscribing

If you are considering the $297-a-year subscription with its 30-day refund, the decision comes down to a few things. O’Dell is a legitimate analyst with a real, verifiable win and a systematic approach, and that is worth something. The Imperium theme, synthetic biology, is genuinely well funded, with serious buyers like Amazon, Eli Lilly, and Anthropic putting real money into DNA technology.

What you should weigh against that is the pricing and the pattern. The pitch asks you to accept that one specific stock is the next IBM, Intel, and Nvidia rolled into one, and that kind of framing has run ahead of the evidence before. For a fuller look at the silicon-layer pick itself, our Twist Bioscience stock piece lays out the financials and the valuation debate in detail.

Ready to see the research? Click here to access Adam O’Dell’s report.


NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.